New combo therapy shows promise for saving rectal cancer Patients' anuses

This study tested whether adding immunotherapy to standard chemoradiation before surgery helps people with a specific type of ultra-low rectal cancer (MSS type). The goal was to increase the chance of a complete response, meaning the tumor disappears, and to preserve the anus and avoid permanent colostomy. The trial involved 201 patients who strongly wanted to keep their anus and were willing to undergo neoadjuvant treatment. Results aim to provide high-level evidence for a new treatment approach.